Natural Killer – licensing a cell therapy

by | Sep 2, 2021

Sectors: Pharmaceuticals

Industries: Medical research

Imperial College London has licensed a new cell therapy technology to Australian company SUDA Pharmaceuticals.

The technology, developed by Professor Tassos Karadimitrus and his team at Imperial’s Centre for Haematology, is based on the invariant natural killer T (iNKT) cell, a rare immune cell.

You can read more about the technology, and the license deal, in this longform article by Dr David Silverman.

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

Related news

Accelerated development of a potential treatment for cystic fibrosis

Accelerated development of a potential treatment for cystic fibrosis

The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Find out more

Natural Killer – licensing a cell therapy

Natural Killer – licensing a cell therapy

Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...